# A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal 

Source: https://onco.cc/trials/nct07293351/  
OnCo record `nct07293351` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PM8002, Ipilimumab, Cabozantinib in renal cell carcinoma, run by Bristol-Myers Squibb, now recruiting.

## Summary

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) is a phase 1/2 interventional study registered as NCT07293351 by Bristol-Myers Squibb, with 474 participants planned, started 2026-03-26 and due to reach its primary completion in 2029-11-28. Interventions recorded: Pumitamig, Ipilimumab, Cabozantinib, Casdatifan. Conditions listed: Advanced Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07293351
- Phase: 1/2
- Setting: ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC)
- Sponsor: Bristol-Myers Squibb
- Enrolled: 474

## Sources

- ClinicalTrials.gov NCT07293351: https://clinicaltrials.gov/study/NCT07293351

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct07293351.json